Lipocine
LPCN
LPCN
49 hedge funds and large institutions have $4.16M invested in Lipocine in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
14% less capital invested
Capital invested by funds: $4.85M → $4.16M (-$694K)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Holders
49
Holding in Top 10
–
Calls
$471K
Puts
$9K
Top Buyers
| 1 | +$35.6K | |
| 2 | +$31.7K | |
| 3 | +$7.2K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.14K |
Top Sellers
| 1 | -$80.9K | |
| 2 | -$42K | |
| 3 | -$20.2K | |
| 4 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$15.9K |
| 5 |
Two Sigma Investments
New York
|
-$15.4K |